Status:
COMPLETED
Umbilical Cord Blood Collection and Processing for Hypoplastic Left Heart Syndrome Patients
Lead Sponsor:
Mayo Clinic
Conditions:
Hypoplastic Left Heart Syndrome (HLHS)
Eligibility:
FEMALE
Phase:
NA
Brief Summary
Cell-based cardiac regeneration has been the focus of acquired, adult heart disease for many years. However, congenital heart disease with severe structural abnormalities may also be reasonable target...
Detailed Description
Congenital heart disease (CHD) is an abnormal formation that occurs during the development of a baby's heart, heart valves and/or large vessels such as the aorta artery. CHD is the most common cause o...
Eligibility Criteria
Inclusion
- Any pregnant woman, regardless of age, with a prenatal diagnosis of severe CHD/hypoplastic left heart syndrome.
- One or both parents willing to consent to the storage of umbilical cord blood for the specific purpose of regenerative research
- Delivering party and/or expectant family is willing to sign Release of Information to request fetal echo text report diagnosing severe CHD/hypoplastic left heart syndrome
- Parent(s) willing to be contacted 60 days after collection for follow-up screening questions regarding the health status of the baby affected with severe CHD/hypoplastic left heart syndrome.
Exclusion
- Individuals unwilling to participate
Key Trial Info
Start Date :
May 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 12 2024
Estimated Enrollment :
464 Patients enrolled
Trial Details
Trial ID
NCT01856049
Start Date
May 1 2012
End Date
November 12 2024
Last Update
January 10 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905
2
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States, 19104